Browse the evidence

Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist that promotes weight loss and glycemic control through synergistic mechanisms including increased glucose-dependent insulin secretion, reduced glucagon, delayed gastric emptying, and increased satiety.

Tirzepatide is a powerful, weekly injectable medication for diabetes and obesity that works by mimicking hormones to control blood sugar and reduce appetite. It requires a prescription, medical supervision, and lifestyle changes (diet/exercise). Using it without medical oversight for aesthetic reasons is dangerous and contributes to drug shortages and fraud.

Dual incretin agonists (specifically GIP/GLP-1 co-agonists like tirzepatide) produce significantly greater weight loss and glycemic reduction than single GLP-1 receptor agonists, effectively closing the treatment gap between pharmacotherapy and bariatric surgery.

If standard GLP-1 medications (like semaglutide or liraglutide) are not delivering sufficient weight loss or blood sugar control, or if side effects prevent you from taking a higher dose, ask your doctor about dual agonists like tirzepatide. These medications target two hormones (GIP and GLP-1) simultaneously and have shown in clinical trials to produce significantly greater weight loss (up to 20%) and better blood sugar control than single-hormone drugs, often with a manageable side effect profile.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces significant weight loss (15-21%) in adults with obesity when administered weekly alongside lifestyle modifications.

If you have obesity or are overweight with related health issues, Tirzepatide is a once-weekly injection that works by mimicking hormones to reduce appetite and slow digestion. In clinical trials, patients lost 15-21% of their body weight over 72 weeks when combining the drug with diet and exercise. While nausea and diarrhea are common side effects, they affect a minority of users. This treatment is intended for long-term management, not short-term fixes.

GLP-1 receptor agonists (semaglutide, liraglutide) and dual GIP/GLP-1 agonists (tirzepatide) induce significant weight loss (5-21%) by suppressing appetite via central nervous system mechanisms and delaying gastric emptying, serving as effective pharmacological alternatives to surgery.

If diet and exercise aren't enough, GLP-1 drugs like Semaglutide (Wegovy) or Tirzepatide (Zepbound) are highly effective pharmacological options. They work by mimicking gut hormones to reduce hunger signals in the brain and slow down digestion. Semaglutide is taken once weekly, while Tirzepatide (a dual agonist) can lead to even greater weight loss (up to 21%). These require a prescription and lifestyle changes, and may cause gastrointestinal side effects like nausea.

Tirzepatide treatment for weight management produces significant weight loss (mean 22.6% over 36 weeks) accompanied by perceived improvements in appetite control, energy levels, and physical functioning, with gastrointestinal side effects being common but generally manageable.

Tirzepatide is a weekly injection approved for weight management in adults with obesity or overweight. Clinical data from the SURMOUNT-4 trial shows an average weight loss of 22.6% over 36 weeks. Patients report significant improvements in appetite control, energy, and physical functioning. Common side effects include nausea and diarrhea, which are often manageable. Most patients found the injection device easy to use and were willing to continue treatment.

Low Energy Availability (LEA) negatively impacts performance and health in both male and female athletes, causing reduced explosive power, endurance, and increased risk of injury and hormonal dysfunction.

Ensure your energy intake matches your expenditure. For both men and women, consuming too few calories relative to activity levels reduces strength, endurance, and increases injury risk. Monitor energy availability, aiming for >45 kcal/kg fat-free mass for healthy adults.

Carbohydrate periodization and strategic timing (loading, intra-exercise intake, post-exercise recovery) significantly support performance and recovery, whereas excessive protein intake above recommendations does not further improve performance.

For events over 90 minutes, use carbohydrate loading (10-12g/kg) 36-48 hours prior. During exercise, consume 30-60g carbs/hour (up to 90g for >2.5h). Post-exercise, prioritize carbs (1.2g/kg) if recovery time is short. Do not exceed protein recommendations as it offers no extra performance benefit.

Daily supplementation with 300 mg of Palmitoylethanolamide (PEA) combined with 8 weeks of resistance training significantly improves lower-body dynamic power (jump height) compared to placebo.

If you want to improve your explosive power (like jumping), adding 300mg of PEA daily to your training routine might help. The study showed a significant improvement in jump height compared to a placebo, suggesting it may support power development alongside strength training.

Cardiac rehabilitation involving structured physical activity significantly reduces cardiovascular mortality and morbidity in patients with coronary heart disease (CHD) and post-myocardial infarction, with a relative risk reduction of 26% compared to no program.

After a heart attack, structured cardiac rehabilitation is not just optional but essential. It reduces your risk of dying from a heart event by about a quarter compared to no program. Start with moderate exercise, focus on consistency, and let your medical team guide the intensity. It is safe and highly effective.

High-Intensity Interval Training (HIIT) improves peak oxygen uptake (VO2peak) more than Moderate-Intensity Continuous Training (MICT) in cardiac patients, although both are safe and effective for improving exercise capacity.

If you are stable after a heart event, High-Intensity Interval Training (HIIT) can boost your fitness (VO2peak) more than steady moderate exercise. However, both are safe. If you are new to exercise or have heart failure, start with moderate intensity and build up volume before trying high intensity.

There is a dose-response relationship between physical activity volume (MET-hours/week) and mortality in CHD patients: doubling activity reduces total mortality by 10%, and 10-20 MET-hours/week reduces mortality by 50% compared to inactive patients.

The more you move, the lower your risk of dying from heart disease. Doubling your activity cuts your risk by 10%. Aim for 10-20 MET-hours per week (e.g., 2-4 hours of moderate walking) to cut your mortality risk by half compared to being inactive.

Personalized nutrition targeting inflammation (PNi) significantly improves body weight, body fat, and inflammatory biomarkers (IL-10, TNF-α, CRP) specifically in individuals with a high genetic predisposition to inflammation (High-PGSi), whereas generic or carbohydrate-focused personalized diets do not yield these specific anti-inflammatory benefits in this subgroup.

If you have a family history of inflammatory conditions or obesity, generic 'healthy eating' advice might not be enough. This research suggests that identifying your genetic risk for inflammation (via a Polygenic Score) allows you to choose a specific anti-inflammatory diet (rich in specific oils, turmeric, and omega-3/6 fats) that can significantly improve your weight, body fat, and inflammatory markers. Without this genetic targeting, standard personalized diets may fail to reduce inflammation in high-risk individuals.

Integrated research-practice partnerships that combine evidence-based lifestyle management (diet, physical activity, behavioral therapy) with healthcare system implementation strategies facilitate the translation of obesity interventions into real-world settings, achieving clinically meaningful weight loss (≥3-5% body weight) and sustainability.

To successfully manage obesity, healthcare systems should adopt integrated research-practice partnerships. This involves combining evidence-based lifestyle strategies (diet, exercise, behavioral therapy) with systematic implementation tools like assessment, shared decision-making, and care coordination. This approach helps achieve clinically meaningful weight loss (3-5% body weight) and sustains these changes within the healthcare system.

Dairy consumption improves bone mineral density (BMD) and reduces fracture risk in adults, primarily through high calcium bioavailability and protein-mediated IGF-1 stimulation, whereas plant-based alternatives generally fail to provide equivalent calcium and protein levels.

To support bone health and reduce fracture risk, prioritize dairy products like milk, yogurt, and cheese. They offer superior calcium bioavailability and protein (stimulating IGF-1) compared to plant-based alternatives. If you have lactose intolerance, choose lactose-free milk or aged cheeses. If you are concerned about heart health, know that current evidence does not support avoiding dairy fat, and low-fat dairy may actually help lower blood pressure. Aim to meet daily calcium recommendations (1000-1300 mg) through these foods, ideally combined with adequate Vitamin D.

Superset resistance training (performing two exercises consecutively with minimal rest) yields equivalent muscular strength, hypertrophy, and body composition adaptations compared to traditional set training, while reducing total session time by approximately 36%.

If you are already experienced with resistance training, you can save about 36% of your gym time by using supersets (pairing two exercises back-to-back with no rest, then resting after the pair) instead of resting between every set. You will get the same muscle and strength gains, but you will feel more fatigued during the session. Ensure you still train to failure and adjust weights to keep reps in the 8-12 range.

Isometric training at long muscle lengths produces similar quadriceps femoris hypertrophy to full range of motion isotonic training in resistance-trained individuals.

If you want to build quad size, you don't necessarily need to do full squats or leg presses. You can use isometric holds at the bottom of the movement (long muscle length) for 30 seconds per set. Do 3-5 sets per session, twice a week, progressively adding sets over 6 weeks. This will build muscle just as well as traditional dynamic leg exercises, provided you are already trained in resistance training.

Adherence to a healthy vegan diet results in greater improvements in overall diet quality (HEI-2015) compared to a healthy omnivore diet, driven by higher intakes of fiber, legumes, and vegetables and lower intakes of added sugars and refined grains.

If you switch to a vegan diet, focus on increasing vegetables, legumes, nuts, seeds, and whole grains while reducing added sugars and refined grains. This study shows that a well-structured vegan diet can improve overall diet quality more than a healthy omnivore diet. Start with delivered meals or meal planning support to build skills, then transition to self-prepared meals. Ensure you monitor Vitamin B12 levels as intake drops without animal products.

Subcutaneous semaglutide 2.4 mg administered once weekly significantly reduces body weight and cardiometabolic risk factors (HbA1c, total cholesterol, systolic blood pressure) in East Asian adults with obesity compared to placebo, though it is associated with higher rates of adverse events.

For East Asian adults with obesity, once-weekly subcutaneous semaglutide (2.4 mg) combined with diet and exercise is a clinically effective treatment for significant body weight reduction and improvement in cardiometabolic risk factors like blood pressure and cholesterol. Patients should be aware that adverse events are more common than with placebo, but the clinical benefits are established.

Tirzepatide (a dual GLP-1RA/GIP agonist) produces superior mean weight loss (18.4%) compared to other FDA-approved pharmacotherapies for obesity, including semaglutide, phentermine-topiramate, and orlistat.

If you have obesity and lifestyle changes alone haven't worked, Tirzepatide is currently the most effective FDA-approved medication for weight loss, showing nearly 18% average weight loss in clinical trials. It requires weekly injections and careful dose titration to manage gastrointestinal side effects, but it offers superior results compared to older drugs like Orlistat or Phentermine-Topiramate.

Semaglutide (a GLP-1RA) produces significant weight loss (10-12.5%) and improves cardiometabolic risk factors, making it more effective than older pharmacotherapies like Phentermine-Topiramate and Orlistat.

Semaglutide is a highly effective weekly injection for weight loss, averaging 10-12% loss in clinical trials. It is more effective than older drugs like Orlistat or Phentermine-Topiramate and also improves heart health markers. It requires weekly injections and titration to manage side effects.

Maintaining a higher proportional energy intake from protein (by limiting discretionary foods) is associated with lower total energy intake and better 12-month weight loss maintenance, whereas diluting protein with high fat/carbohydrate leads to increased energy intake and weight regain via the protein leverage mechanism.

To maintain weight loss, prioritize foods that keep your protein percentage high relative to fats and carbs. Avoid 'discretionary' foods (sweets, processed snacks) which dilute protein concentration and trigger overeating. You don't necessarily need to increase total protein grams, but you must increase its proportion in your diet by reducing low-protein energy sources.

GLP-1 receptor agonists (semaglutide 2.4 mg weekly) significantly improve pain and function in patients with obesity and moderate-to-severe knee osteoarthritis, achieving clinical benefits comparable to or exceeding standard therapies like NSAIDs and physical therapy.

If you have knee osteoarthritis and a BMI over 30, GLP-1 medications like semaglutide (2.4 mg weekly) can significantly reduce pain and improve function, potentially delaying or avoiding surgery. This works not just by helping you lose weight, but by directly reducing inflammation in the joint. Current guidelines suggest aiming for more than 7-10% weight loss for maximum benefit, which these drugs help achieve more effectively than lifestyle changes alone for many people.

Once-weekly subcutaneous semaglutide 2.4 mg combined with diet and exercise reverses prediabetes in approximately 80% of patients with obesity, significantly outperforming diet and exercise alone (12% reversal rate).

If you have obesity and prediabetes, adding once-weekly semaglutide 2.4 mg to your diet and exercise plan significantly increases your chances of reversing prediabetes (from 12% to 80%). This treatment also lowers BMI by ~14% and reduces cardiovascular risks. It requires weekly injections and ongoing lifestyle efforts, as stopping the drug may lead to weight regain and return of prediabetes.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) induce significant weight loss (14.9%–20.9%) and improve fertility in obese individuals, particularly those with PCOS, by acting on hypothalamic and brainstem regions to suppress appetite and stimulate GnRH/LH release.

GLP-1 agonists like semaglutide and tirzepatide are highly effective for significant weight loss and can improve fertility in obese individuals, especially those with PCOS. However, they come with high rates of gastrointestinal side effects and weight regain upon discontinuation. They should be used under medical supervision, with careful attention to dosing and long-term management strategies.